Autres langues Chugai Pharmaceutical Co., Ltd.

Actions

4519

JP3519400000

Produits pharmaceutiques

Marché Fermé - Japan Exchange 08:30:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
6 225,00 ^JPY	+2,12%		-7,72%	-24,48%

29/09	Chugai Pharmaceutical Co., Ltd. : Jefferies & Co. n'est pas inspiré par le dossier	ZM
28/09	Le Swiss Market Index ouvre la semaine sans relief ; Roche recule lors de sa Pharma Day	MT

Autres langues

28/09	Healthcare Stocks Rise to Start Week -- Healthcare Roundup
28/09	Swiss Market Index Opens Week Muted; Roche Falls Amid Pharma Day
28/09	Roche to End Future Development of Obesity Drug Emugrobart
28/09	Chugai Pharmaceutical Co., Ltd. Announces Discontinuation of Development of Gym329 for Obesity, Return of License and Resumption of Development for Sma
28/09	Roche stoppt Entwicklung von Adipositas-Medikament
28/09	Roche Halts Development of Obesity Drug Candidate
28/09	Chugai Pharmaceutical to Discontinue Obesity Drug Development
28/09	Roche-Tochter Chugai beendet Entwicklung von Emugrobart bei Übergewicht
23/09	Chugai Pharma to Boost Capex by 50% to Expand In-House Production
16/09	Roche-Tochter Chugai baut Einsatz seines Krebstests in Japan aus
10/09	Tres investigadores de Chugai que participaron en el descubrimiento de Hemlibra para la hemofilia A reciben el prestigioso Lasker-DeBakey Clinical Medical Research Award, uno de los máximos reconocimientos científicos del mundo
10/09	Drei Chugai-Forscher, die hinter der Entdeckung von Hemlibra zur Behandlung von Hämophilie A stehen, erhalten renommierten US-amerikanischen Lasker Award, eine der weltweit angesehensten wissenschaftlichen Ehrungen
09/09	Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
25/08	Roche-Tochter Chugai reicht Zulassungsantrag für Vamikibart in Japan ein
21/08	Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets
18/08	Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
18/08	Chugai grants GSK exclusive global license for AID351 dengue antibody
14/08	Roche-Tochter Chugai beantragt zusätzliche Zulassung für Tecentriq
14/08	Japanese shares climb on bets Fed to hold rates steady; Topix poised for record close
14/08	Chugai Pharmaceutical Co., Ltd. Files For Additional Indication Of Tecentriq For Adjuvant Treatment Of MSI-High Colon Cancer
07/08	Chugai und University of California kooperieren in der Wirkstoffforschung
04/08	Phylo, Inc. and Chugai Pharmaceutical Co., Ltd. Partner to Advance Ai Agents in Drug Discovery
31/07	Chugai Pharmaceutical Files For Additional Indication Of Enspryng For Prevention Of Relapse In MOG Antibody-Associated Disease In Japan
30/07	Chugai Pharmaceutical Co., Ltd. - Support for Areas Affected by the 2026 Kumamoto Prefecture Earthquake
27/07	Chugai Announces 2026 2nd Quarter Results